BAVARIAN NORDIC/S (BVNRY) to Release Earnings on Thursday
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) will be posting its quarterly earnings results before the market opens on Thursday, August 15th. Analysts expect BAVARIAN NORDIC/S to post earnings of ($0.13) per share for the quarter.
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last announced its quarterly earnings data on Wednesday, May 22nd. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.04). The business had revenue of $19.29 million during the quarter, compared to the consensus estimate of $21.15 million. BAVARIAN NORDIC/S had a negative return on equity of 12.56% and a negative net margin of 45.38%. On average, analysts expect BAVARIAN NORDIC/S to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of BVNRY opened at $8.80 on Wednesday. The company has a market cap of $852.98 million, a price-to-earnings ratio of -14.92 and a beta of 0.59. The company has a current ratio of 9.34, a quick ratio of 9.01 and a debt-to-equity ratio of 0.22. BAVARIAN NORDIC/S has a fifty-two week low of $5.92 and a fifty-two week high of $9.73. The business has a 50 day simple moving average of $8.55.
About BAVARIAN NORDIC/S
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.
Featured Story: Neutral Rating
Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.